SequelSEC

NEUROONE MEDICAL TECHNOLOGIES Corp NMTC

Surgical & Medical Instruments & Apparatus · CIK 0001500198 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
$9.47M
Fiscal year ended 2026-06-30
Operating income
-$7.90M
Fiscal year ended 2026-06-30
Free cash flow
-$7.16M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$25.50MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-03-31
Float per share$0.51Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-03-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-09-30 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth163.5%96th
CapEx / revenue0.9%22th
R&D / revenue54.8%77th
Current ratio4.44x69th
SBC / revenue13.9%66th
Operating margin-46.5%38th
Net margin-39.6%40th
Gross margin56.5%41th
FCF margin-32.1%41th

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) reported revenue of $9.47M and net income of -$7.45M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from NEUROONE MEDICAL TECHNOLOGIES Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NEUROONE MEDICAL TECHNOLOGIES Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$9.47M
Cost of revenue$4.20M
Gross profit$5.27M
Operating income-$7.90M
Net income-$7.45M
Research & development$5.40M
Weighted-average diluted sharesUnavailable
Pretax income-$7.45M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$7.77M
General & administrative$6.00M
Selling & marketingUnavailable

Balance

NEUROONE MEDICAL TECHNOLOGIES Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$2.05M
Total assets$6.19M
Current assets$5.79M
Total liabilities$2.42M
Current liabilities$2.04M
Total equity incl. NCI$3.77M
Temporary (mezzanine) equityUnavailable
Inventory$2.29M
Accounts receivable$1.10M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$905.72K

Cash flow

NEUROONE MEDICAL TECHNOLOGIES Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$7.05M
Capital expenditures$109.54K
Investing cash flow-$109.54K
Financing cash flow$1.17M
Net change in cashUnavailable
Stock-based compensation$1.41M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$236.88K

Derived

NEUROONE MEDICAL TECHNOLOGIES Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$7.16M
Gross margin55.6%
Operating margin-83.4%
FCF margin-75.6%
SBC / revenue14.9%
Current ratio2.84x
Revenue YoY growth42.8%
Net margin-78.6%
R&D / revenue57.0%
CapEx / revenue1.2%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NMTC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q/A · Filed 2026-06-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-K · Filed 2025-12-17View SEC filing
10-Q · Filed 2025-08-14View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.